Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment

Exclusion Criteria

• •1. Hypersensitivity or intolerance to statins, ezetimibe, or PCSK9 inhibitors.
• •2. Hemorrhagic stroke, active bleeding, severe trauma or major surgery within 6 months before enrollment.
• •3. Malignancy (expected survival \<3 years), severe liver/kidney disease, or autoimmune disease.
• •4. Cognitive impairment (MoCA \<20) or psychiatric disorders precluding assessment cooperation.
• •5. Pregnant, breastfeeding, or planning pregnancy during the trial.
• •6. Participation in other clinical trials or use of other lipid-lowering drugs within 3 months.
• •7. Poor compliance or other conditions judged by investigators to interfere with the study.